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Extracorporeal circulation (ECC) is an invaluable tool in lung 
transplantation (lutx). More than the past years, an increasing 
number of centers changed their standard for intraoperative 
ECC from cardiopulmonary bypass (CPB) to extracorporeal 
membrane oxygenation (ECMO) – with differing results. This 
meta-analysis reviews the existing evidence. An online literature 
research on Medline, Embase, and PubMed has been performed. 
Two persons independently judged the papers using the ACRO-
BAT-NRSI tool of the Cochrane collaboration. Meta-analyses and 
meta-regressions were used to determine whether veno-arterial 
ECMO (VA-ECMO) resulted in better outcomes compared with 
CPB. Six papers – all observational studies without randomization 
– were included in the analysis. All were considered to have seri-
ous bias caused by heparinization as co-intervention. Forest plots 
showed a beneficial trend of ECMO regarding blood transfusions 
(packed red blood cells (RBCs) with an average mean difference 
of −0.46 units [95% CI = −3.72, 2.80], fresh-frozen plasma with 
an average mean difference of −0.65 units [95% CI = −1.56, 
0.25], platelets with an average mean difference of −1.72 units 
[95% CI = −3.67, 0.23]). Duration of ventilator support with 
an average mean difference of −2.86 days [95% CI = −11.43, 
5.71] and intensive care unit (ICU) length of stay with an average 
mean difference of −4.79 days [95% CI = −8.17, −1.41] were 
shorter in ECMO patients. Extracorporeal membrane oxygen-
ation treatment tended to be superior regarding 3 month mortal-
ity (odds ratio = 0.46, 95% CI = 0.21–1.02) and 1 year mortality 
(odds ratio = 0.65, 95% CI = 0.37–1.13). However, only the ICU 
length of stay reached statistical significance. Meta-regression 
analyses showed that heterogeneity across studies (sex, year of 
ECMO implementation, and underlying disease) influenced dif-
ferences. These data indicate a benefit of the intraoperative use 
of ECMO as compared with CPB during lung transplant proce-
dures regarding short-term outcome (ICU stay). There was no 
statistically significant effect regarding blood transfusion needs 
or long-term outcome. The superiority of ECMO in lutx patients 
remains to be determined in larger multi-center randomized tri-
als. ASAIO Journal 2017; 63:551–561.
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Extracorporeal circulation (ECC) plays a pivotal role throughout 
the care of lung transplantation (lutx) patients: pre- and post-
operatively, extracorporeal membrane oxygenation (ECMO) is 
used as a bridge to transplant or as a rescue therapy for primary 
graft failure.1,2 Intraoperatively, ECC helps to overcome exces-
sive pulmonary hypertension and associated right heart fail-
ure after clamping of the pulmonary hilum or global hypoxia 
and hypercarbia during one lung ventilation.3–5 Whereas in the 
past, there has been controversy about the benefit and risks of 
routine ECC use during lutx procedures, there is growing evi-
dence that patients undergoing lutx on ECC support receive 
more blood products, have longer mechanical ventilation time, 
and prolonged intensive care unit (ICU) and hospital length of 
stay.6 There is a higher risk of bleeding and an elevated need for 
re-thoracotomies in these patients. However, overall mortality 
does not seem to be affected.6 Therefore, routine ECC use in 
lutx is overcome in most centers and intraoperative ECC use is 
restricted to cases necessitating it only. Centers report an intra-
operative ECC use in 20–40% of patients.5–11 Open-circuit car-
diopulmonary bypass (CPB) is the standard and most familiar 
modality used for intraoperative cardiorespiratory support and in 
some centers lutxs are routinely performed on full bypass.6,7,10,12 
However, passage of blood through the circuit activates inflam-
matory reactions and the mandatory full heparinization may 
induce coagulation disorders, bleeding complications, and an 
increased need of blood transfusions.11,13–15 Further, Diamond et 
al. identified the use of CPB as an independent risk factor of 
severe primary graft failure which in turn is one of the major 
causes of death within the first year after lutx.16,17
Along with advances in ECMO technology and a growing 
experience in ECMO therapy, an increasing number of lutx 
centers switched their practice regarding the intraoperative 
extracorporeal support from CPB to ECMO.5,8,10,11,18,19 Because 
of the increase in the number of patients supported by ECMO 
pre- or postoperatively, intraoperative ECMO use is of high 
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versatility and allows integrated perioperative patient manage-
ment.6 Whereas first reports of intraoperative ECMO replacing 
CPB date back to 2001,19 the majority of centers switched to 
the routine use of ECMO intraoperatively from 2008 on. The 
data published so far vary considerably. Although some studies 
concluded CPB still being the method of choice,20 other found 
advantageous outcomes with ECMO.10,11,18 Given the lack of 
definitive data on the efficacy of ECMO in lutx, we conducted 
meta-analyses to summarize the current evidence on the use of 
ECMO versus CPB in patients undergoing lutx.
Methods
Search Strategy and Selection Criteria
We systematically searched PubMed, Medline, and Embase, 
with no language restriction, for studies comparing intraopera-
tive ECMO to CPB for lutx on cardiopulmonary support regard-
ing transfusion needs, mechanical ventilation duration, and 
outcome and survival parameters. The search was performed 
from database commencement to December 2016. Our core 
search consisted of terms related to ECMO and CPB, combined 
with lutx (see Appendix 1, Supplemental Digital Content, 
http://links.lww.com/ASAIO/A139).
Inclusion criteria relating to participants are limited to 
patients undergoing either single or sequential double lutx, of 
any age, of any indication, of any waiting list time, requiring 
intraoperative extracorporeal support (ECMO or CPB), without 
bridge to transplant extracorporeal support, without combined 
transplants such as heart-lung transplantation or lung-liver 
transplantation, but including minor concomitant cardiac sur-
gery. We included studies if they reported either intraoperative 
RBC transfusion, intraoperative fresh frozen plasma transfu-
sion, intraoperative platelet transfusion, duration of postopera-
tive ventilation support, length of ICU stay, or mortality rate.
Two investigators (DH, YMS) assessed the eligibility of each 
study independently. The studies that were not published as 
full reports, such as conference abstracts, were excluded. We 
scrutinized the reference lists of the identified reports and 
other relevant publications to find additional pertinent studies. 
No additional studies were found.
Data Extraction and Quality Assessment
For all eligible studies, data extraction was undertaken inde-
pendently by two investigators (DH is an anesthesiologist in 
training and YMS is a trained researcher in clinical research 
methodology) using a modified version of the Cochrane Col-
laboration data extraction form.21 The extracted information 
included population, setting, study design, baseline demo-
graphics and operation procedures for each group, study out-
comes, and statistical methods. Subsequently, methodological 
quality was assessed by using a Cochrane risk of bias assess-
ment tool for nonrandomized studies of intervention.22 The tool 
covers seven domains: bias caused by confounding, bias in 
selection of participants into the study, bias in measurement 
of interventions, bias caused by departures from intended 
intervention, bias caused by missing data, bias in measure-
ment of outcomes, and bias in selection of the reported results. 
The overall risk of bias was derived from the judgment across 
domains. Both investigators have double checked the extracted 
data and risk of bias assessment. Disagreements were resolved 
by discussion between the two review investigators.
Statistical Analysis
We used the raw mean difference when meta-analyzing a 
set of studies comparing ECMO versus CPB with respect to 
continuous outcomes, such as intraoperative RBC transfusion 
(units), intraoperative fresh frozen plasma transfusion (units), 
intraoperative platelet transfusion (units), duration of post-
operative ventilation support (days), and length of ICU stay 
(days). When comparing mortality rate between ECMO and 
CPB across studies, the odds ratios were used. We estimated 
the pooled mean differences and pooled odds ratios by use of 
inverse-variance weight in fixed-effect or random-effect (Der-
Simonian and Laird) meta-analysis according to heterogeneity 
between studies. Sensitivity analyses were also performed to 
Figure 1. Flow diagram of study selection.
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identify the robustness of our findings after excluding an out-
lier study. The I2 statistics and Q statistic were used to identify 
heterogeneity between studies. Because we were concerned 
about the variation in results across studies, meta-regression 
analyses for each outcome of interest were used to explore 
study-level factors that contribute to heterogeneity between 
studies. Several potential factors were selected, including 
mean age, proportion of male, body mass index, proportion of 
underlying diagnosis (e.g. idiopathic pulmonary fibrosis, cystic 
fibrosis, and chronic obstructive pulmonary disease), mean of 
lung allocation scores (LAS), mean pulmonary artery pressure, 
and the year that the ECMO was implemented (because there 
is no information in Bittner et al. study, we took the median 
year during the recruitment period). Only studies reporting the 
number or mean of CPB and ECMO for each baseline category 
were included in meta-regression analyses. To assess publica-
tion bias, funnel plots were constructed for each outcome, and 
applied regression methods to determine funnel plot asym-
metry.23 Statistical analyses were performed using the software 
package R language version 3.1.2.
Results
Of seven articles found in three databases (Medline, Embase, 
and PubMed), we identified six articles which met the inclu-
sion criteria. Figure 1 shows our search, selection process, and 
the reasons for exclusion. The studies by Akarsu et al., Ius et 
al., and, Ko et al. were excluded because they did not compare 
ECMO and CPB use but reported experience using ECMO in 
lutx.6,19,24 Yu et al. used CPB as a primary choice in all patients 
who were undergoing lutx but used ECMO if patients were 
bridged to the transplant on extracorporeal support. This does 
not fairly compare the two systems, implements a huge bias, 
and did not meet the inclusion criteria.25 Two investigators (DH 
and YMS) agreed on all included papers.5,8,10,11,18,20
The six studies were published in English and from 2007 
onwards (Table 1): all were retrospective cohort studies. In 
Machuca et al. study, they used a 1:2 matched design for the 
sake of reducing confounding. Three studies stated that ECMO 
has been implemented since 2012, two other studies indicated 
the time point of interest at 2011 and 2010, respectively. One 
group did not provide the year of change to ECMO but must 
have done so from 2003 to 2005. Heparin use was considered 
to being a co-intervention for ECMO and CPB: all studies stated 
that high dose heparinization was used in CPB patients. With 
regard to ECMO patients, low dose heparinization was used in 
four studies; in the study by Hoechter et al. all but four ECMO 
patients received low dose heparinization, four received a full 
dose. Bittner et al. state aiming for an activating clotting time 
(ACT) of >450 s for CPB patients and an ACT of 160–220 s for 
ECMO patients but do not provide the heparin doses used. 
There was no imbalance baseline characteristic shown in the 
study by Machuca et al. and Bittner et al. because of matching 
approach and limited reporting, respectively. The studies of Ius 
et al. and Bittner et al. were adjusted for the potential con-
founding factors. The possible factors of heterogeneity varied 
greatly across studies. All studies were judged to have serious 
risk of bias caused by heparin co-intervention.
Figure 2 shows the results of meta-analyses of mean differ-
ence (ECMO versus CPB) with respect to intraoperative blood 
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blood transfusion requirement seemed to show a tendency 
toward a benefit of ECMO, but the differences did not reach 
significance. The meta-analysis demonstrated a 0.46 reduc-
tion in the unit of RBCs requirement with ECMO intervention 
(mean difference −0.46; 95 CI% = −3.72, 2.80), a 0.65 reduc-
tion in the unit of fresh-frozen plasma requirement with ECMO 
intervention (mean difference −0.65; 95 CI% = −1.56, 0.25), 
and a 1.72 reduction in the unit of platelets requirement with 
ECMO intervention (mean difference −1.72; 95 CI% = −3.67, 
0.23), respectively. There was heterogeneity of the benefit of 
ECMO between studies shown in the analyses of RBCs and 
platelets requirement. Determining heterogeneity between 
studies is commonly based on Q statistic. A p value of <0.05 
means that the benefit of ECMO varies from one study to the 
next. In such case, the summary mean difference under the 
random-effect model is considered, otherwise the one under 
the fixed-effect model.
Figure 3 shows the results of the meta-analyses of mean dif-
ference (ECMO versus CPB) in the duration of ventilator sup-
port and ICU stay. The meta-analyses demonstrated a shorter 
duration of ventilator support (mean difference −2.86; 95 CI% 




Figure 2. Forest plot showing the mean differences in intraoperative blood transfusion requirement (units). A: Packed RBCs; B: fresh-frozen 
plasma; C: platelets. (Mean difference below 0 favor ECMO whereas mean difference above 0 favor CPB.) RBC, red blood cell; ECMO, extra-
corporeal membrane oxygenation; CPB, cardiopulmonary bypass.
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= −8.17, −1.41) for patients with ECMO intervention compared 
with patients with CPB intervention. There was a statistically 
significant difference in the mean duration of the ICU stay. 
There was heterogeneity of the benefit of ECMO between stud-
ies shown in the analyses of the duration of ventilator support.
With regard to mortality, the benefit of ECMO intervention 
was reflected in a 54% lower mortality rate at 3 month (OR = 
0.46, 95% CI: 0.21, 1.02) compared with that observed in the 
CPB group, but did not reach statistical significance. Analyzing 
the 6 month mortality rate, our results show a 12% increase in 
the risk of mortality after ECMO intervention compared with 
CPB intervention (OR = 1.12, 95% CI: 0.55, 2.28), although 
there was no significant difference. When the observation 
period was extended to one year, ECMO decreased the risk 
of mortality by 35% compared with the CPB group (OR 0.65; 
95% CI: 0.37, 1.13) (Figure 4), but again this result lacks the 
statistical significance. There is no heterogeneity of the benefit 
of ECMO between studies because Q statistic shows nonsig-
nificant difference. The summary mean difference under fixed-
effect model was considered.
There was little evidence of funnel plot symmetry for each 
outcome because of the small number of studies included.
In meta-regression analyses, the advantage of ECMO was 
substantially influenced by the heterogeneity across the stud-
ies (Table 2). The advantage of ECMO in intraoperative RBCs 
requirement may depend on the proportion of male patients, 
as CPB seemed to be superior, the higher the proportion of 
male was (Table 2, Figure 5A). The results indicate that 1% 
increase in proportion of male corresponds to a change of 
0.28 units, in terms of the mean difference of intraoperative 
RBC requirement (ECMO versus CPB). Here we displayed 
the bubble plots that are an informative tool to interpret the 
regression of coefficients in meta-regression. In a bubble plot, 
each study is represented by a corresponding circle. The size of 
each circle is proportional to that study’s weight in the analy-
sis. The solid line shows the predicted difference in intraopera-
tive RBC requirements. Three studies under the equator (such 
as the study performed in Hoechter et al., Biscotti et al., and 
Ius et al., whose proportion of male are 41%, 51%, and 52%, 
respectively) would have a benefit from ECMO (corresponding 
to mean difference of intraoperative RBCs requirement near 
−4.58, −1.64, and −5.10, respectively).
Similarly, the year that the ECMO was implemented had 
substantial effect on mean difference of intraoperative RBCs 
requirement (Figure 5B). The year that the ECMO was imple-
mented in Hoechter et al., Biscotti et al., and Ius et al. were 
2012, 2012, and 2010, respectively. Three studies under the 
equator would have a benefit from ECMO. The use of ECMO 
would reduce intraoperative RBCs requirement near 4.58, 
1.64, and 5.10 units, respectively.
We repeated analyses with potential factors on mean dif-
ference of intraoperative fresh-frozen plasma, intraoperative 
platelets requirement, postoperative duration of ventilator 
support, and mortality rate. The heterogeneity of the effect of 
A
B
Figure 3. Forest plot showing the mean differences in duration of ventilator support and ICU stay (days). A: Ventilator support; B: ICU stay. 
(Mean difference below 0 favor ECMO whereas mean difference above 0 favor CPB.) CPB, cardiopulmonary bypass; ECMO, extracorporeal 
membrane oxygenation; ICU, intensive care unit.
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ECMO was caused by proportion of male patients and the diag-
noses of cystic fibrosis, chronic obstructive pulmonary disease, 
and idiopathic pulmonary fibrosis; furthermore the mean LAS, 
and the year that the ECMO program has been implemented 
influenced the association between outcome measurement 
and advantage of ECMO (Table 2 and bubble plots shown in 
Appendix 2, Supplemental Digital Content, http://links.lww.
com/ASAIO/A140).
Discussion
Our meta-analysis systemically examined the effects of veno-
arterial ECMO (VA-ECMO) versus CPB during lutx surgery. The 
results show comparable outcomes for patients on ECMO and 
CPB regarding to blood transfusion requirements, duration of 
mechanical ventilation, or survival. A significant improvement 
for the ECMO group was observed in the length of ICU stay. 
Our findings show a trend toward favorable survival rates at 3 
month among ECMO patients although results lacked statisti-
cal significance. However, the outcome differences between 
ECMO and CPB were affected by heterogeneity across study 
characteristics.
Meta-analyses of observational studies are prone to biases, 
caused, for example, by confounding and deviating from 
intended interventions. Three studies were trying to adjust con-
founding factors by using matching approach in study design 
stage,10 multivariate analyses with propensity matching,5 and 




Figure 4. Forest plot showing the odds ratios for mortality. A: 3 month mortality; B: 6 month mortality; C: 1 year mortality. (Odds ratio 
below 1 favor ECMO whereas odds ratio above 1 favor CPB.) ECMO, extracorporeal membrane oxygenation; CPB, cardiopulmonary bypass.
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performed multivariate analyses by categorizing outcome vari-
ables, we may doubt that the results came from data dredging. 
Therefore, we consider that the results from the prior two stud-
ies are less prone to bias.
With regards to bias caused by deviations from intended 
intervention, heparinization is a critical co-intervention unbal-
anced between ECMO group and CPB group. A low dose 
heparinization is currently used for ECMO patients whereas 
a full dose heparinization is administered necessarily for CPB 
patients. From what we know so far, running ECMOs with 
a low dose heparinization does not seem to cause a mark-
edly increased rate of thromboembolic complications.26 In 
the study of Hoechter et al., the results show that the patients 
with high dose heparinization required more blood transfu-
sion during operation than those with low dose heparinization 
– irrespective of the types of ECC used.11 Because hepariniza-
tion is used to achieve the desired anticoagulation level, intra-
operative blood transfusion requirement may favor the ECMO 
group (less intraoperative blood transfusion requirement in the 
ECMO group).
In this regard, another aspect is the use of cell savers ver-
sus pericardial suction: both seem to have negative influence 
on coagulation and inflammation, yet to different degrees and 
hereby can influence blood loss and transfusion needs.27,28 
Only the studies of Hoechter et al. and Biscotti et al. men-
tion the use of a cell saver and provide cell saver retransfusion 
volumes in both ECMO and CPB patient groups. None of the 
studies provides any details regarding the use of pericardial 
suction.
For intraoperative RBCs requirement, however, there was no 
statistically significant evidence of a beneficial effect of ECMO. 
There are two studies showing that their ECMO group received 
relatively more RBCs: in the study by Bermudez et al., the 
ECMO group has higher proportion of preoperative ECMO use. 
The consecutive activation of coagulation and inflammation 
and the ongoing hemolysis may result in higher blood cells 
requirement.8,29 In the study by Bittner et al., because there are 
no unbalance patient characteristics between the two groups, 
they speculated that liberal volume replacement and preven-
tion of transcapillary leakage with interstitial edema formation 
may be the main reasons for the increased use of red blood 
transfusion in the ECMO group.20 Our meta-regression analy-
ses revealed that gender and the year that ECMO was imple-
mented significantly influence the difference of intraoperative 
RBC requirements between groups: studies with predomi-
nantly male patients and performed in an earlier era tended to 
favor CPB use. We found that in the study by Bittner et al., 87% 
patients were male and the ECMO was implemented between 
2003 and 2005; these are much higher and earlier than those 
of other four studies, respectively. Thus, we performed sensitiv-
ity analysis based on the other four studies. However, the result 
remained unchanged because the small sample size of Bittner 
et al. study gave little weight for the pooled mean difference. 
All studies showed a trend toward a reduction of the platelet 
transfusion rate in the ECMO group; however, the effect did 
not achieve statistical significance. Weber et al. showed that a 
higher number of intraoperative blood transfusions was asso-
ciated with increased mortality in lung transplant recipients, 
reasonable best efforts to minimize blood transfusions should 
be made.16,30
Moreover, a large-volume blood product transfusion, has 
been identified as a risk factor of severe primary graft dysfunc-
tion (PGD)16,31; PGD typically occurs during the first 3 days after 
lutx. Poor oxygenation is the main characteristic of the condi-
tion. It is further characterized by a low pulmonary compliance, 
interstitial or alveolar edema, pulmonary infiltrates on chest 
radiographs, increased pulmonary vascular resistance, intrapul-
monary shunt, and acute alveolar injury.32 Additional risk factors 
conclude elevated pulmonary artery pressures, a high fraction 
of inspired oxygen during allograft reperfusion, and the use of 
Table 2.  Univariate Meta-Regression Analysis of Potential Factors of Heterogeneity Across the Published Studies; Showing  
Significant Results Only
 No. of Study Mean Difference [95% CI] p Value
Intraoperative blood transfusion    
 RBCs requirement (units)    
 Intercept  −16.28 [−25.19 to −7.37] 0.0034
 Proportion of male 5 0.28 [0.13 to 0.44] 0.0004
 Intercept  2,354.2 [243.5 to 4,464.8] 0.0288
 The year that the ECMO was implemented 5 −1.17 [−2.22 to −0.12] 0.0288
 Fresh-frozen plasma requirement (units)    
 Intercept  4.02 [−0.21 to 8.25] 0.0624
 Proportion of cystic fibrosis 4 −0.27 [−0.51 to −0.03] 0.0266
 Intercept  24.4 [4.09 to 44.7] 0.0185
 Mean LAS at transplant 3 −0.43 [−0.78 to −0.08] 0.0153
 Platelets requirement (units)    
 Intercept  1.85 [−0.83 to 4.53] 0.1753
 Proportion of COPD 4 −0.29 [−0.50 to −0.09] 0.0047
Postoperative outcomes    
 Duration of ventilator support (days)    
 Intercept  −28.92 [−44.67 to −13.17] 0.0003
 Proportion of male 4 0.41 [0.19 to 0.63] 0.0003
 Intercept  −20.71 [−32.72 to −8.71] 0.0007
 Proportion of IPF 4 0.37 [0.16 to 0.58] 0.0005
 Intercept  3,829.8 [1,735.6 to 5,924.1] 0.0003
 The year that the ECMO was implemented 4 −1.91 [−2.95 to −0.86] 0.0003
COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; RBC, red blood cell; ECMO, extracorporeal membrane 
oxygenation; LAS, lung allocation score.
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CPB.16 The International Society for Heart and Lung Transplanta-
tion grades the severity according to the paO2–FiO2 ratio and 
the radiographic findings.33 Only two of the studies separately 
assessed the incidence of PGD: in the study by Ius et al. the 
incidence of severe PGD did not differ between groups.5 Bermu-
dez et al. found that the CPB group was more likely to have any 
PGD at 24 and 72 h post transplantation than the ECMO group; 
in addition, the severity of PGD was lower in the ECMO group.18
Figure 5. A: Bubble plot showing the mean difference in intraoperative RBCs requirement (units) versus proportion of male. B: Bubble plot 
showing the mean difference in intraoperative RBCs requirement (units) versus the year that ECMO was implemented in the study. ECMO, 
extracorporeal membrane oxygenation; RBC, red blood cell.
Copyright © American Society of Artificial Internal Organs. Unauthorized reproduction of this article is prohibited.
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All but the study by Bittner et al. found a trend toward a 
shorter ventilation time in the ECMO group. This study was 
performed very early on. More than the past eight years, the 
emphasis on lung protective ventilation gained importance 
in the field of lutx; the use of lower tidal volumes resulted 
in a reduced inflammation reaction and shorter durations of 
postoperative mechanical ventilation.34 Nowadays, early extu-
bation should be regarded as the best option in the postopera-
tive period, as it minimizes complications such as pulmonary 
infections.34 Some centers even evaluate the use of a very early 
extubation strategy aiming for a termination of invasive ventila-
tion right after the transplant procedure.35 For patients who do 
not quite tolerate this rapid extubation, the immediate institu-
tion of noninvasive positive pressure ventilation might be an 
option.34
To allow for lung protective ventilation even in case of reper-
fusion edema or primary graft failure, extracorporeal support 
might be extended into the postoperative care. Postoperative 
ECMO use ranges from 10.6% to 55% in ECMO patients and 
5.5–27% in CPB patients.8,11,18 Here, an extension of the intra-
operative support is associated with a better outcome com-
pared with secondary inserted ECMOs.34,36
Patients who were intraoperatively supported by ECMO had 
a significantly shorter ICU stay. Seiler et al. recently identified 
a long ICU stay as a risk factor for a lower health related qual-
ity of life in lutx patients.37 Furthermore, prolonged ICU stay is 
associated with an increased mortality rate.38 In this context, 
the shorter ICU stay in the ECMO group is not only a statisti-
cally significant difference but also a clinically relevant advan-
tage. Therefore, it is not surprising that there was a trend seen 
toward a decreased mortality 3 months after the transplant 
procedure. However, in the mid- and long-term, there was no 
difference in the mortality between the groups. Whereas early 
deaths after lutx are attributable to perioperative complica-
tions, uncontrollable bleedings or primary graft failure, death 
in the long-term is because of multifactorial origin including 
graft rejection, lethal infections, and complications of a pro-
longed ICU and hospital stay. It is questionable whether effects 
on the long-term can still be attributed to the intraoperative 
extracorporeal support technique. Further research on the cau-
sality of death is needed to then improve long-term survival.
This systematic review has several limitations. First, a small 
number of studies were included in this review. The studies are 
not controlled or randomized trials but retrospective analyses of 
case series. Furthermore, all of the studies had a historical con-
trol group; therefore the results are unaccounted for other devel-
opments in lutx such as advances in surgical techniques and the 
grade of experience of the physicians’ team or the change in the 
lutx population after introduction of the LAS.39 Observational 
studies rarely provide sufficiently robust evidence to recom-
mend changes to clinical practice or health policy decision-
making. However, for reasons such as little case numbers and 
ethical concerns, these are the only ones available for certain 
topics such as extracorporeal support in lutx.
Conclusion
In conclusion, this meta-analysis summarizes the experi-
ence of intraoperative ECMO versus CPB in lutx. Still, there 
are no clear-cut advantages of one system over the other. Only 
the ICU length of stay was shorter in the ECMO group. There 
was no statistically significant effect regarding the remaining 
parameters. More studies are needed to further clarify which 
patient population benefits from what extracorporeal support 
technique. Because we have an ongoing scarcity of organs 
available, it must be the unanimous aim to provide best pos-
sible care to all lung transplant patients.
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